Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Metastatic Renal Cell Carcinoma and Melanoma With Subsequential High-Dose Subcutaneous Interferon Alfa-2b and High-Dose Bolus and Continuous Intravenous Interleukin-2

NCT00003091 is registered in ClinicalTrials.gov with Hoag Memorial Hospital Presbyterian as lead sponsor.

NCT NCT00003091
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003091 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Metastatic Renal Cell Carcinoma and Melanoma With Subsequential High-Dose Subcutaneous Interferon Alfa-2b and High-Dose Bolus and Continuous Intravenous Interleukin-2
Lead sponsor
Hoag Memorial Hospital Presbyterian
Phase
Phase 2
Overall status
Completed
Start date
January 31, 1996
Completion date
January 31, 2000
Enrollment
40 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

kidney cancer, melanoma (skin)